Caplacizumab and immunosuppressive therapy without first line therapeutic plasma exchange in adults with immune-mediated thrombotic thrombocytopenic purpura Caplacizumab and immunosuppressive therapy without first line therapeutic plasma exchange in adults ...
An open-label, single-arm, multicenter study to evaluate the efficacy and safety of caplacizumab and immunosuppressive therapy without first line therapeutic plasma exchange in adults with immune-mediated thrombotic thrombocytopenic purpura An open-label, single-arm, multicenter study to evaluate the efficacy and safety of caplacizumab and ...
Thrombotic Thrombocytopenic Purpura MedDRA version: 20.0;Level: PT;Classification code 10043648;Term: Thrombotic thrombocytopenic purpura;System Organ Class: 10005329 - Blood and lymphatic system disorders;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15] Thrombotic Thrombocytopenic Purpura MedDRA version: 20.0;Level: PT;Classification code 10043648;Term ...
Trade Name: Cablivi® Product Name: Cablivi® Product Code: ALX0081 INN or Proposed INN: Caplacizumab Other descriptive name: Nanobody directed towards the human A1 domain of von Willebrand factor Trade Name: Cablivi® Product Name: Cablivi® Product Code: ALX0081 INN or Proposed INN: Caplacizumab Other descriptive name: Nanobody directed towards the human A1 domain of von Willebrand factor Trade Name: Cablivi® Product Name: Cablivi® Product Code: ALX0081 INN or Proposed INN: Caplacizumab Othe ...
Sanofi-Aventis Recherche & Développement
NULL
Authorised-recruitment may be ongoing or finished
Female: yes Male: yes
64
Phase 3
United States;Czechia;Greece;Spain;Austria;United Kingdom;Switzerland;Italy;France;Czech Republic;Canada;Belgium;Germany;Netherlands;Japan United States;Czechia;Greece;Spain;Austria;United Kingdom;Switzerland;Italy;France;Czech Republic;Ca ...